<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BEPREVE- bepotastine besilate solution/ drops </strong><br>Bausch &amp; Lomb Incorporated<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use BEPREVE<span class="Sup">®</span> (bepotastine besilate ophthalmic solution) 1.5% safely and effectively.  See full prescribing information for BEPREVE<span class="Sup">®</span>. <br>BEPREVE<span class="Sup">®</span> (bepotastine besilate ophthalmic solution) 1.5%<br>Initial U.S. Approval: 2009</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Contraindications (<a href="#i4i_contraindications_id_6035e6c1-8f1e-435a-b718-8e5b3b794793">4</a>)  06/2012  </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">BEPREVE<span class="Bold"><span class="Sup">® </span></span>is a histamine H1 receptor antagonist indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> associated with <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>. (<a href="#i4i_indications_id_b3e0eecf-4c5e-4970-a7c7-d61d1241c0a5">1</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">Instill one drop into the affected eye(s) twice a day (BID). (<a href="#i4i_dosage_admin_id_e0cdc649-ba04-4c4d-af02-1ba57b13c3d4">2</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Solution containing bepotastine besilate, 1.5%. (<a href="#i4i_dosage_form_strength_id_7b0b2943-6f19-41ae-81f4-b69acbe38ced">3</a>)  </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>To minimize the risk of contamination, do not touch dropper tip to any surface. Keep bottle tightly closed when not in use. (<a href="#i4i_warnings_precautions_duplicate_id_d1b36345-a434-4905-8c84-8d94cdf0f0af">5.1</a>) </dd>
<dt>•</dt>
<dd>BEPREVE should not be used to treat contact lens-related irritation. (<a href="#i4i_warnings_precautions_duplicate_id_d1b36345-a434-4905-8c84-8d94cdf0f0af">5.2</a>) </dd>
<dt>•</dt>
<dd>Remove contact lenses prior to instillation of BEPREVE. (<a href="#i4i_warnings_precautions_duplicate_id_d1b36345-a434-4905-8c84-8d94cdf0f0af">5.2</a>) </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"> The most common adverse reaction occurring in approximately 25% of patients was a mild taste following instillation. Other adverse reactions which occurred in 2-5% of subjects were <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>. (<a href="#i4i_adverse_effects_id_eacf265a-417e-4038-9809-1b63dadb140c">6</a>)  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Bausch &amp; Lomb Incorporated. at 1-800-323-0000, or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.      </span> </p>
</div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 10/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Contamination of Tip and Solution</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Contact Lens Use</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Topical Ophthalmic Use Only</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-9.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-10" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-11" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-12" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-13" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-13.1" class="toc">17.1 Topical Ophthalmic Use Only</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_b3e0eecf-4c5e-4970-a7c7-d61d1241c0a5"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">BEPREVE<span class="Sup">®</span> (bepotastine besilate ophthalmic solution) 1.5% is a histamine H<span class="Sub">1</span> receptor antagonist indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> associated with signs and symptoms of <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_e0cdc649-ba04-4c4d-af02-1ba57b13c3d4"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Instill one drop of BEPREVE into the affected eye(s) twice a day (BID).</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_7b0b2943-6f19-41ae-81f4-b69acbe38ced"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Topical ophthalmic solution containing bepotastine besilate 1.5%.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_6035e6c1-8f1e-435a-b718-8e5b3b794793"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Bepreve is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to bepotastine or any of the other ingredients <span class="Italics">[see Adverse Reactions (6.2)]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_e464a90b-a738-4bb4-9791-42862979fa66"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_022164f8-aac0-4c5a-97ba-2d59e9a0a267"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Contamination of Tip and Solution</h2>
<p class="First">To minimize contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_d1b36345-a434-4905-8c84-8d94cdf0f0af"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Contact Lens Use</h2>
<p class="First">Patients should be advised not to wear a contact lens if their eye is red. BEPREVE should not be used to treat contact lens-related irritation.</p>
<p>BEPREVE should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of BEPREVE. The preservative in BEPREVE, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of BEPREVE.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_3ccdbdd3-0640-48f3-bb48-4cddaf565eb0"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Topical Ophthalmic Use Only</h2>
<p class="First">BEPREVE is for topical ophthalmic use only.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_eacf265a-417e-4038-9809-1b63dadb140c"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_duplicate_id_93eee7ae-14b1-493b-a7bd-39dde7a9c9e5"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The most common reported adverse reaction occurring in approximately 25% of subjects was a mild taste following instillation. Other adverse reactions occurring in 2-5% of subjects were <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>. </p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_duplicate_id_e19ef50d-0fa5-491b-b6f8-ab6930148836"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post Marketing Experience</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> have been reported rarely during the post-marketing use of BEPREVE. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a casual relationship to drug exposure. The <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> include <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, body <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="44783305" conceptname="Lip swelling">swelling of lips</span>, tongue and/or throat.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_91b23203-14e2-4436-8732-93681ef061e5"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_2195d18a-ff13-413a-b646-851be8fe10d4"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category C: </span><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> studies have been performed in animals. Bepotastine besilate was not found to be teratogenic in rats during organogenesis and fetal development at oral doses up to 200 mg/kg/day (representing a systemic concentration approximately 3,300 times that anticipated for topical ocular use in humans), but did show some potential for causing skeletal abnormalities at 1,000 mg/kg/day. There were no teratogenic effects seen in rabbits at oral doses up to 500 mg/kg/day given during organogenesis and fetal development (&gt;13,000 times the dose in humans on a mg/kg basis). Evidence of <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> was seen in rats given oral bepotastine besilate 1,000 mg/kg/day; however, no evidence of <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> was observed in rats given 200 mg/kg/day (approximately 3,300 times the topical ocular use in humans). The concentration of radio-labeled bepotastine besilate was similar in fetal liver and maternal blood plasma following a single 3 mg/kg oral dose. The concentration in other fetal tissues was one-third to one-tenth the concentration in maternal blood plasma.</p>
<p>An increase in stillborns and decreased growth and development were observed in pups born from rats given oral doses of 1,000 mg/kg/day during perinatal and lactation periods. There were no observed effects in rats treated with 100 mg/kg/day. There are no adequate and well-controlled studies of bepotastine besilate in pregnant women. Because animal reproduction studies are not always predictive of human response, BEPREVE<span class="Sup">®</span> (bepotastine besilate ophthalmic solution) 1.5% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_4a1796da-11c5-4bce-8b92-a33524abe59e"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Following a single 3 mg/kg oral dose of radiolabeled bepotastine besilate to nursing rats 11 days after delivery, the maximum concentration of radioactivity in milk was 0.40 mcg-eq/mL 1 hour after administration; at 48 hours after administration the concentration was below detection limits. The milk concentration was higher than the maternal blood plasma concentration at each time of measurement.</p>
<p>It is not known if bepotastine besilate is excreted in human milk. Caution should be exercised when BEPREVE (bepotastine besilate ophthalmic solution) 1.5% is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_0e0815fd-fbd4-4e06-b583-41ca89f9488d"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and efficacy of BEPREVE (bepotastine besilate ophthalmic solution) 1.5% have not been established in pediatric patients under 2 years of age. Efficacy in pediatric patients under 10 years of age was extrapolated from clinical trials conducted in pediatric patients greater than 10 years of age and from adults.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_f29f28b3-767a-4f6d-a204-4cdea56c1a3f"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">No overall difference in safety or effectiveness has been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_94542c8b-e8fa-4f89-a45e-4f70eaa06c07"></a><a name="section-8"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">BEPREVE (bepotastine besilate ophthalmic solution) 1.5% is a sterile, topically administered drug for ophthalmic use. Each mL of BEPREVE contains 15 mg bepotastine besilate. Bepotastine besilate is designated chemically as (+) -4-[[(S)-p-chloro-alpha -2-pyridylbenzyl]oxy]-1- piperidine butyric acid monobenzenesulfonate. The chemical structure for bepotastine besilate is:</p>
<div class="Figure">
<a name="id425"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=68bbf6a0-c4b5-47c1-8a1c-08220fbdbce6&amp;name=e8c7bd70-e024-4a70-81c9-0bf4a35e3b3c-01.jpg">
</div>
<p>Bepotastine besilate is a white or <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellowish crystalline powder. The molecular weight of bepotastine besilate is 547.06 daltons. BEPREVE<span class="Sup">®</span> ophthalmic solution is supplied as a sterile, aqueous 1.5% solution, with a pH of 6.8. The <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of BEPREVE (bepotastine besilate ophthalmic solution) 1.5% is approximately</p>
<p>290 mOsm/kg.</p>
<p><span class="Bold">Each mL of BEPREVE<span class="Sup">®</span> (bepotastine besilate ophthalmic solution) 1.5% contains:</span></p>
<p><span class="Bold">Active:  </span>Bepotastine besilate 15 mg (equivalent to 10.7 mg bepotastine)</p>
<p><span class="Bold">Preservative: </span>benzalkonium chloride 0.005%</p>
<p><span class="Bold">Inactives: </span>monobasic sodium phosphate dihydrate, sodium chloride, sodium hydroxide to adjust pH, and water for injection, USP.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_ed009f73-445e-4879-a844-72e55f73e1ff"></a><a name="section-9"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_c58478c0-c15a-4aab-bf25-5452a8c97ab9"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Bepotastine is a topically active, direct H1-receptor antagonist and an inhibitor of the release of histamine from mast cells.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_a4acdfee-d181-424b-aaad-50b711e38d74"></a><a name="section-9.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold">Absorption: </span>The extent of systemic exposure to bepotastine following topical ophthalmic administration of bepotastine besilate 1% and 1.5% ophthalmic solutions was evaluated in 12 healthy adults. Following one drop of 1% or 1.5% bepotastine besilate ophthalmic solution to both eyes four times daily (QID) for seven days, bepotastine plasma concentrations peaked at approximately one to two hours post-instillation. Maximum plasma concentration for the 1% and 1.5% strengths were 5.1 ± 2.5 ng/mL and 7.3 ± 1.9 ng/mL, respectively. Plasma concentration at 24 hours post-instillation were below the quantifiable limit (2 ng/mL) in 11/12 subjects in the two dose groups.</p>
<p><span class="Bold">Distribution: </span>The extent of protein binding of bepotastine is approximately 55% and independent of bepotastine concentration.</p>
<p><span class="Bold">Metabolism: </span><span class="Italics">In vitro </span>metabolism studies with human liver microsomes demonstrated that bepotastine is minimally metabolized by CYP450 isozymes. <span class="Italics">In vitro </span>studies demonstrated that bepotastine besilate does not inhibit the metabolism of various cytochrome P450 substrate via inhibition of CYP3A4, CYP2C9, and CYP2C19. The effect of bepotastine besilate on the metabolism of substrates of CYP1A2, CYP2C8, CYP2D6 was not studied. Bepotastine besilate has a low potential for drug interaction via inhibition of CYP3A4, CYP2C9, and CYP2C19.</p>
<p><span class="Bold">Excretion: </span>The main route of elimination of bepotastine besilate is urinary excretion (with approximately 75-90% excreted unchanged in urine).</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_87c4f653-02b8-4da7-a883-3de20a03c023"></a><a name="section-10"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_4296a17f-3a52-4a38-99be-5290e9cf3ee1"></a><a name="section-10.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term dietary studies in mice and rats were conducted to evaluate the carcinogenic potential of bepotastine besilate. Bepotastine besilate did not significantly induce neoplasms in mice receiving a nominal dose of up to 200 mg/kg/day for 21 months or rats receiving a nominal dose of up to 97 mg/kg/day for 24 months. These dose levels represent systemic exposures approximating 350 and 200 times that achieved with human topical ocular use. The no observable adverse effect levels for bepotastine besilate based on nominal dose levels in carcinogenicity tests were 18.7 to 19.9 mg/kg/day in mice and 9.6 to 9.8 mg/kg/day in rats (representing exposure margins of approximately 60 and 20 times the systemic exposure anticipated for topical ocular use in humans).</p>
<p>There was no evidence of genotoxicity in the Ames test, in CHO cells (chromosome aberrations), in mouse hepatocytes (unscheduled DNA synthesis), or in the mouse micronucleus test.</p>
<p>When oral bepotastine was administered to male and female rats at doses up to 1,000 mg/kg/day, there was a slight reduction in fertility index and surviving fetuses. <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span> was not seen in rats given 200 mg/kg/day oral bepotastine besilate (approximately 3,300 times the systemic concentration anticipated for topical ocular use in humans).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_ced5b8c7-107b-4a0d-94b7-75fdf7a75b53"></a><a name="section-11"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Clinical efficacy was evaluated in 2 conjunctival allergen challenge (CAC) studies (237 patients). BEPREVE (bepotastine besilate ophthalmic solution) 1.5% was more effective than its vehicle for relieving <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">ocular itching</span> induced by an ocular allergen challenge, both at a CAC 15 minutes post-dosing and a CAC 8 hours post dosing of BEPREVE.</p>
<p>The safety of BEPREVE was evaluated in a randomized clinical study of 861 subjects over a period of 6 weeks.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_fe4fc6aa-25bc-42de-a408-dede133d8175"></a><a name="section-12"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">BEPREVE<span class="Sup">®</span> (bepotastine besilate ophthalmic solution) 1.5% is supplied in a white low density polyethylene plastic squeeze bottle with a white controlled dropper tip and a white polypropylene cap in the following size:</p>
<p>5 mL (NDC 24208-629-02) </p>
<p>10 mL (NDC 24208-629-01)</p>
<p>STORAGE</p>
<p>Store at 15° – 25°C (59° – 77°F).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_79a64763-d5f7-4859-bede-c51f363aa49a"></a><a name="section-13"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_duplicate_id_4d944003-46c0-43dd-9aa8-38c915d6037d"></a><a name="section-13.1"></a><p></p>
<h2>17.1 Topical Ophthalmic Use Only</h2>
<p class="First">For topical ophthalmic administration only.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_duplicate_id_d2716950-0a60-4b87-90a7-b12b492cee15"></a><a name="section-13.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Sterility</span> of Dropper Tip</h2>
<p class="First">Patients should be advised to not touch dropper tip to any surface, as this may contaminate the contents.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_duplicate_id_e7f77f37-5a6d-42f1-9b95-f6c84ed858e7"></a><a name="section-13.3"></a><p></p>
<h2>17.3 Concomitant Use of Contact Lenses</h2>
<p class="First">Patients should be advised not to wear a contact lens if their eye is red. Patients should be advised that BEPREVE should not be used to treat contact lens-related irritation.</p>
<p>Patients should also be advised to remove contact lenses prior to instillation of BEPREVE. The preservative in BEPREVE, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of BEPREVE.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_694f53a4-f71f-4797-88dd-3344c1c58020"></a><a name="section-14"></a><p></p>
<p class="First">Manufactured by: Bausch &amp; Lomb Incorporated</p>
<p>Tampa, FL 33637</p>
<p>Under license from:</p>
<p>Senju Pharmaceutical Co., Ltd.</p>
<p>Osaka, Japan 541-0046</p>
<p>®/TM are trademarks of Bausch &amp; Lomb Incorporated or its affiliates</p>
<p>© 2012 Bausch &amp; Lomb Incorporated.</p>
<p>9291000 (flat)<br>9291100 (folded)<br>Revised 10/2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_1d5a5112-f2ab-4a49-b2ac-25aa6a0cceb0"></a><a name="section-15"></a><p></p>
<p class="First">NDC 24208-629-01</p>
<p>BEPREVE®</p>
<p>(bepotastine besilate ophthalmic solution) 1.5%</p>
<p>Sterile 10 mL</p>
<p>Rx only</p>
<p>Bausch &amp; Lomb</p>
<div class="Figure">
<a name="id581"></a><img alt="10 mL Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=68bbf6a0-c4b5-47c1-8a1c-08220fbdbce6&amp;name=e8c7bd70-e024-4a70-81c9-0bf4a35e3b3c-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BEPREVE 		
					</strong><br><span class="contentTableReg">bepotastine besilate solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24208-629</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BEPOTASTINE BESILATE</strong> (BEPOTASTINE) </td>
<td class="formItem">BEPOTASTINE BESILATE</td>
<td class="formItem">15 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem">0.05 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24208-629-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:24208-629-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:24208-629-03</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022288</td>
<td class="formItem">09/08/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Bausch &amp; Lomb Incorporated
							(196603781)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bausch &amp; Lomb Incorporated</td>
<td class="formItem"></td>
<td class="formItem">079587625</td>
<td class="formItem">MANUFACTURE(24208-629)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a51ed9aa-d631-4ce7-9fa6-f83c9dc7d661</div>
<div>Set id: 68bbf6a0-c4b5-47c1-8a1c-08220fbdbce6</div>
<div>Version: 5</div>
<div>Effective Time: 20141001</div>
</div>
</div> <div class="DistributorName">Bausch &amp; Lomb Incorporated</div></p>
</body></html>
<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BEPREVE- bepotastine besilate solution/ drops </strong><br>Bausch &amp; Lomb Incorporated<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use BEPREVE<span class="Sup">®</span> (bepotastine besilate ophthalmic solution) 1.5% safely and effectively.  See full prescribing information for BEPREVE<span class="Sup">®</span>. <br>BEPREVE<span class="Sup">®</span> (bepotastine besilate ophthalmic solution) 1.5%<br>Initial U.S. Approval: 2009</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Contraindications (<a href="#i4i_contraindications_id_6035e6c1-8f1e-435a-b718-8e5b3b794793">4</a>)  06/2012  </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">BEPREVE<span class="Bold"><span class="Sup">® </span></span>is a histamine H1 receptor antagonist indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> associated with <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>. (<a href="#i4i_indications_id_b3e0eecf-4c5e-4970-a7c7-d61d1241c0a5">1</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">Instill one drop into the affected eye(s) twice a day (BID). (<a href="#i4i_dosage_admin_id_e0cdc649-ba04-4c4d-af02-1ba57b13c3d4">2</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Solution containing bepotastine besilate, 1.5%. (<a href="#i4i_dosage_form_strength_id_7b0b2943-6f19-41ae-81f4-b69acbe38ced">3</a>)  </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>To minimize the risk of contamination, do not touch dropper tip to any surface. Keep bottle tightly closed when not in use. (<a href="#i4i_warnings_precautions_duplicate_id_d1b36345-a434-4905-8c84-8d94cdf0f0af">5.1</a>) </dd>
<dt>•</dt>
<dd>BEPREVE should not be used to treat contact lens-related irritation. (<a href="#i4i_warnings_precautions_duplicate_id_d1b36345-a434-4905-8c84-8d94cdf0f0af">5.2</a>) </dd>
<dt>•</dt>
<dd>Remove contact lenses prior to instillation of BEPREVE. (<a href="#i4i_warnings_precautions_duplicate_id_d1b36345-a434-4905-8c84-8d94cdf0f0af">5.2</a>) </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"> The most common adverse reaction occurring in approximately 25% of patients was a mild taste following instillation. Other adverse reactions which occurred in 2-5% of subjects were <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>. (<a href="#i4i_adverse_effects_id_eacf265a-417e-4038-9809-1b63dadb140c">6</a>)  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Bausch &amp; Lomb Incorporated. at 1-800-323-0000, or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>.      </span> </p>
</div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 10/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Contamination of Tip and Solution</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Contact Lens Use</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Topical Ophthalmic Use Only</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-9.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-10" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-11" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-12" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-13" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-13.1" class="toc">17.1 Topical Ophthalmic Use Only</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_b3e0eecf-4c5e-4970-a7c7-d61d1241c0a5"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">BEPREVE<span class="Sup">®</span> (bepotastine besilate ophthalmic solution) 1.5% is a histamine H<span class="Sub">1</span> receptor antagonist indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> associated with signs and symptoms of <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_e0cdc649-ba04-4c4d-af02-1ba57b13c3d4"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Instill one drop of BEPREVE into the affected eye(s) twice a day (BID).</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_7b0b2943-6f19-41ae-81f4-b69acbe38ced"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Topical ophthalmic solution containing bepotastine besilate 1.5%.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_6035e6c1-8f1e-435a-b718-8e5b3b794793"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Bepreve is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to bepotastine or any of the other ingredients <span class="Italics">[see Adverse Reactions (6.2)]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_e464a90b-a738-4bb4-9791-42862979fa66"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_022164f8-aac0-4c5a-97ba-2d59e9a0a267"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Contamination of Tip and Solution</h2>
<p class="First">To minimize contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_d1b36345-a434-4905-8c84-8d94cdf0f0af"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Contact Lens Use</h2>
<p class="First">Patients should be advised not to wear a contact lens if their eye is red. BEPREVE should not be used to treat contact lens-related irritation.</p>
<p>BEPREVE should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of BEPREVE. The preservative in BEPREVE, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of BEPREVE.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_duplicate_id_3ccdbdd3-0640-48f3-bb48-4cddaf565eb0"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Topical Ophthalmic Use Only</h2>
<p class="First">BEPREVE is for topical ophthalmic use only.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_eacf265a-417e-4038-9809-1b63dadb140c"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_duplicate_id_93eee7ae-14b1-493b-a7bd-39dde7a9c9e5"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The most common reported adverse reaction occurring in approximately 25% of subjects was a mild taste following instillation. Other adverse reactions occurring in 2-5% of subjects were <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>. </p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_duplicate_id_e19ef50d-0fa5-491b-b6f8-ab6930148836"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post Marketing Experience</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> have been reported rarely during the post-marketing use of BEPREVE. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a casual relationship to drug exposure. The <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> include <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, body <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="44783305" conceptname="Lip swelling">swelling of lips</span>, tongue and/or throat.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_91b23203-14e2-4436-8732-93681ef061e5"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_2195d18a-ff13-413a-b646-851be8fe10d4"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category C: </span><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> studies have been performed in animals. Bepotastine besilate was not found to be teratogenic in rats during organogenesis and fetal development at oral doses up to 200 mg/kg/day (representing a systemic concentration approximately 3,300 times that anticipated for topical ocular use in humans), but did show some potential for causing skeletal abnormalities at 1,000 mg/kg/day. There were no teratogenic effects seen in rabbits at oral doses up to 500 mg/kg/day given during organogenesis and fetal development (&gt;13,000 times the dose in humans on a mg/kg basis). Evidence of <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> was seen in rats given oral bepotastine besilate 1,000 mg/kg/day; however, no evidence of <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> was observed in rats given 200 mg/kg/day (approximately 3,300 times the topical ocular use in humans). The concentration of radio-labeled bepotastine besilate was similar in fetal liver and maternal blood plasma following a single 3 mg/kg oral dose. The concentration in other fetal tissues was one-third to one-tenth the concentration in maternal blood plasma.</p>
<p>An increase in stillborns and decreased growth and development were observed in pups born from rats given oral doses of 1,000 mg/kg/day during perinatal and lactation periods. There were no observed effects in rats treated with 100 mg/kg/day. There are no adequate and well-controlled studies of bepotastine besilate in pregnant women. Because animal reproduction studies are not always predictive of human response, BEPREVE<span class="Sup">®</span> (bepotastine besilate ophthalmic solution) 1.5% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_4a1796da-11c5-4bce-8b92-a33524abe59e"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Following a single 3 mg/kg oral dose of radiolabeled bepotastine besilate to nursing rats 11 days after delivery, the maximum concentration of radioactivity in milk was 0.40 mcg-eq/mL 1 hour after administration; at 48 hours after administration the concentration was below detection limits. The milk concentration was higher than the maternal blood plasma concentration at each time of measurement.</p>
<p>It is not known if bepotastine besilate is excreted in human milk. Caution should be exercised when BEPREVE (bepotastine besilate ophthalmic solution) 1.5% is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_0e0815fd-fbd4-4e06-b583-41ca89f9488d"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and efficacy of BEPREVE (bepotastine besilate ophthalmic solution) 1.5% have not been established in pediatric patients under 2 years of age. Efficacy in pediatric patients under 10 years of age was extrapolated from clinical trials conducted in pediatric patients greater than 10 years of age and from adults.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_f29f28b3-767a-4f6d-a204-4cdea56c1a3f"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">No overall difference in safety or effectiveness has been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_94542c8b-e8fa-4f89-a45e-4f70eaa06c07"></a><a name="section-8"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">BEPREVE (bepotastine besilate ophthalmic solution) 1.5% is a sterile, topically administered drug for ophthalmic use. Each mL of BEPREVE contains 15 mg bepotastine besilate. Bepotastine besilate is designated chemically as (+) -4-[[(S)-p-chloro-alpha -2-pyridylbenzyl]oxy]-1- piperidine butyric acid monobenzenesulfonate. The chemical structure for bepotastine besilate is:</p>
<div class="Figure">
<a name="id425"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=68bbf6a0-c4b5-47c1-8a1c-08220fbdbce6&amp;name=e8c7bd70-e024-4a70-81c9-0bf4a35e3b3c-01.jpg">
</div>
<p>Bepotastine besilate is a white or <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellowish crystalline powder. The molecular weight of bepotastine besilate is 547.06 daltons. BEPREVE<span class="Sup">®</span> ophthalmic solution is supplied as a sterile, aqueous 1.5% solution, with a pH of 6.8. The <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of BEPREVE (bepotastine besilate ophthalmic solution) 1.5% is approximately</p>
<p>290 mOsm/kg.</p>
<p><span class="Bold">Each mL of BEPREVE<span class="Sup">®</span> (bepotastine besilate ophthalmic solution) 1.5% contains:</span></p>
<p><span class="Bold">Active:  </span>Bepotastine besilate 15 mg (equivalent to 10.7 mg bepotastine)</p>
<p><span class="Bold">Preservative: </span>benzalkonium chloride 0.005%</p>
<p><span class="Bold">Inactives: </span>monobasic sodium phosphate dihydrate, sodium chloride, sodium hydroxide to adjust pH, and water for injection, USP.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_ed009f73-445e-4879-a844-72e55f73e1ff"></a><a name="section-9"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_c58478c0-c15a-4aab-bf25-5452a8c97ab9"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Bepotastine is a topically active, direct H1-receptor antagonist and an inhibitor of the release of histamine from mast cells.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_a4acdfee-d181-424b-aaad-50b711e38d74"></a><a name="section-9.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold">Absorption: </span>The extent of systemic exposure to bepotastine following topical ophthalmic administration of bepotastine besilate 1% and 1.5% ophthalmic solutions was evaluated in 12 healthy adults. Following one drop of 1% or 1.5% bepotastine besilate ophthalmic solution to both eyes four times daily (QID) for seven days, bepotastine plasma concentrations peaked at approximately one to two hours post-instillation. Maximum plasma concentration for the 1% and 1.5% strengths were 5.1 ± 2.5 ng/mL and 7.3 ± 1.9 ng/mL, respectively. Plasma concentration at 24 hours post-instillation were below the quantifiable limit (2 ng/mL) in 11/12 subjects in the two dose groups.</p>
<p><span class="Bold">Distribution: </span>The extent of protein binding of bepotastine is approximately 55% and independent of bepotastine concentration.</p>
<p><span class="Bold">Metabolism: </span><span class="Italics">In vitro </span>metabolism studies with human liver microsomes demonstrated that bepotastine is minimally metabolized by CYP450 isozymes. <span class="Italics">In vitro </span>studies demonstrated that bepotastine besilate does not inhibit the metabolism of various cytochrome P450 substrate via inhibition of CYP3A4, CYP2C9, and CYP2C19. The effect of bepotastine besilate on the metabolism of substrates of CYP1A2, CYP2C8, CYP2D6 was not studied. Bepotastine besilate has a low potential for drug interaction via inhibition of CYP3A4, CYP2C9, and CYP2C19.</p>
<p><span class="Bold">Excretion: </span>The main route of elimination of bepotastine besilate is urinary excretion (with approximately 75-90% excreted unchanged in urine).</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_87c4f653-02b8-4da7-a883-3de20a03c023"></a><a name="section-10"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_4296a17f-3a52-4a38-99be-5290e9cf3ee1"></a><a name="section-10.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term dietary studies in mice and rats were conducted to evaluate the carcinogenic potential of bepotastine besilate. Bepotastine besilate did not significantly induce neoplasms in mice receiving a nominal dose of up to 200 mg/kg/day for 21 months or rats receiving a nominal dose of up to 97 mg/kg/day for 24 months. These dose levels represent systemic exposures approximating 350 and 200 times that achieved with human topical ocular use. The no observable adverse effect levels for bepotastine besilate based on nominal dose levels in carcinogenicity tests were 18.7 to 19.9 mg/kg/day in mice and 9.6 to 9.8 mg/kg/day in rats (representing exposure margins of approximately 60 and 20 times the systemic exposure anticipated for topical ocular use in humans).</p>
<p>There was no evidence of genotoxicity in the Ames test, in CHO cells (chromosome aberrations), in mouse hepatocytes (unscheduled DNA synthesis), or in the mouse micronucleus test.</p>
<p>When oral bepotastine was administered to male and female rats at doses up to 1,000 mg/kg/day, there was a slight reduction in fertility index and surviving fetuses. <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span> was not seen in rats given 200 mg/kg/day oral bepotastine besilate (approximately 3,300 times the systemic concentration anticipated for topical ocular use in humans).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_ced5b8c7-107b-4a0d-94b7-75fdf7a75b53"></a><a name="section-11"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Clinical efficacy was evaluated in 2 conjunctival allergen challenge (CAC) studies (237 patients). BEPREVE (bepotastine besilate ophthalmic solution) 1.5% was more effective than its vehicle for relieving <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">ocular itching</span> induced by an ocular allergen challenge, both at a CAC 15 minutes post-dosing and a CAC 8 hours post dosing of BEPREVE.</p>
<p>The safety of BEPREVE was evaluated in a randomized clinical study of 861 subjects over a period of 6 weeks.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_fe4fc6aa-25bc-42de-a408-dede133d8175"></a><a name="section-12"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">BEPREVE<span class="Sup">®</span> (bepotastine besilate ophthalmic solution) 1.5% is supplied in a white low density polyethylene plastic squeeze bottle with a white controlled dropper tip and a white polypropylene cap in the following size:</p>
<p>5 mL (NDC 24208-629-02) </p>
<p>10 mL (NDC 24208-629-01)</p>
<p>STORAGE</p>
<p>Store at 15° – 25°C (59° – 77°F).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_79a64763-d5f7-4859-bede-c51f363aa49a"></a><a name="section-13"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_duplicate_id_4d944003-46c0-43dd-9aa8-38c915d6037d"></a><a name="section-13.1"></a><p></p>
<h2>17.1 Topical Ophthalmic Use Only</h2>
<p class="First">For topical ophthalmic administration only.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_duplicate_id_d2716950-0a60-4b87-90a7-b12b492cee15"></a><a name="section-13.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Sterility</span> of Dropper Tip</h2>
<p class="First">Patients should be advised to not touch dropper tip to any surface, as this may contaminate the contents.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_duplicate_id_e7f77f37-5a6d-42f1-9b95-f6c84ed858e7"></a><a name="section-13.3"></a><p></p>
<h2>17.3 Concomitant Use of Contact Lenses</h2>
<p class="First">Patients should be advised not to wear a contact lens if their eye is red. Patients should be advised that BEPREVE should not be used to treat contact lens-related irritation.</p>
<p>Patients should also be advised to remove contact lenses prior to instillation of BEPREVE. The preservative in BEPREVE, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of BEPREVE.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_694f53a4-f71f-4797-88dd-3344c1c58020"></a><a name="section-14"></a><p></p>
<p class="First">Manufactured by: Bausch &amp; Lomb Incorporated</p>
<p>Tampa, FL 33637</p>
<p>Under license from:</p>
<p>Senju Pharmaceutical Co., Ltd.</p>
<p>Osaka, Japan 541-0046</p>
<p>®/TM are trademarks of Bausch &amp; Lomb Incorporated or its affiliates</p>
<p>© 2012 Bausch &amp; Lomb Incorporated.</p>
<p>9291000 (flat)<br>9291100 (folded)<br>Revised 10/2012</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_1d5a5112-f2ab-4a49-b2ac-25aa6a0cceb0"></a><a name="section-15"></a><p></p>
<p class="First">NDC 24208-629-01</p>
<p>BEPREVE®</p>
<p>(bepotastine besilate ophthalmic solution) 1.5%</p>
<p>Sterile 10 mL</p>
<p>Rx only</p>
<p>Bausch &amp; Lomb</p>
<div class="Figure">
<a name="id581"></a><img alt="10 mL Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=68bbf6a0-c4b5-47c1-8a1c-08220fbdbce6&amp;name=e8c7bd70-e024-4a70-81c9-0bf4a35e3b3c-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BEPREVE 		
					</strong><br><span class="contentTableReg">bepotastine besilate solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24208-629</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BEPOTASTINE BESILATE</strong> (BEPOTASTINE) </td>
<td class="formItem">BEPOTASTINE BESILATE</td>
<td class="formItem">15 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem">0.05 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24208-629-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:24208-629-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:24208-629-03</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022288</td>
<td class="formItem">09/08/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Bausch &amp; Lomb Incorporated
							(196603781)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bausch &amp; Lomb Incorporated</td>
<td class="formItem"></td>
<td class="formItem">079587625</td>
<td class="formItem">MANUFACTURE(24208-629)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a51ed9aa-d631-4ce7-9fa6-f83c9dc7d661</div>
<div>Set id: 68bbf6a0-c4b5-47c1-8a1c-08220fbdbce6</div>
<div>Version: 5</div>
<div>Effective Time: 20141001</div>
</div>
</div> <div class="DistributorName">Bausch &amp; Lomb Incorporated</div></p>
</body></html>
